AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire

AstraZeneca (AZN) has received positive CHMP recommendations in the EU for two key label expansions: Koselugo for adult patients with inoperable plexiform neurofibromas associated with NF1, backed by the KOMET study's 20% objective response rate, and Tezspire (co-developed with Amgen) for chronic rhinosinusitis with nasal polyps, based on Phase III WAYPOINT data showing significant clinical benefits. These endorsements signal potential market expansion and increased revenue opportunities for AZN and its partners in the European market, building on current approvals and strategic collaborations.

Analysis

AstraZeneca (AZN) has secured two positive recommendations from the European Medicines Agency's CHMP, signaling a strong likelihood of expanded EU market approvals for Koselugo and Tezspire. For Koselugo, the recommendation for adult patients with NF1-associated plexiform neurofibromas is supported by Phase III KOMET study data showing a 20% objective response rate versus 5% for placebo, expanding its use from the pediatric population. This development will trigger a profit-sharing agreement with Merck (MRK). Simultaneously, the CHMP nod for Tezspire, co-developed with Amgen (AMGN), for chronic rhinosinusitis with nasal polyps is based on compelling Phase III WAYPOINT data demonstrating a significant reduction in polyp severity and need for surgery. This European progress precedes a U.S. FDA decision for the same indication expected by October 19, 2025. These regulatory milestones reinforce the strength of AstraZeneca's pipeline and contribute to its notable 18.2% year-to-date stock rally, which substantially outpaces the industry's 3.5% rise.

Key Decisions for Investors

• Investors should view the dual CHMP recommendations as a de-risking event for AstraZeneca's European revenue forecasts, supporting the stock's premium valuation and recent outperformance against the sector.
• The upcoming U.S. FDA decision for Tezspire in October 2025 represents a key future catalyst; a positive outcome would unlock a significantly larger market and could serve as a major value inflection point for both AstraZeneca and its partner Amgen.
• While the news is primarily a positive for AstraZeneca, the financial impact on partners Merck and Amgen should be considered; the Koselugo revenue is shared, and the Tezspire alliance structure validates the value of these collaborations, offering modest incremental upside to MRK and AMGN.